

CRCM

Cancer Research
Center of Marseille



External Seminar Series

Tuesday June 25, 2024

11:00 AM, IPC2 Amphitheater

Hosted by OHIO Department



Guillaume BOSSIS

Institut de Génétique
Moléculaire de Montpellier
(IGMM), Montpellier

“SUMO: A novel target to enhance Acute Myeloid Leukemias response to epigenetic therapies and boost Natural Killer cells anti-leukemic activity ”

Abstract: SUMO-1, -2 and -3 are post-translational modifiers conjugated to thousands of proteins to modify their function and fate. Using various preclinical models, we have demonstrated that TAK-981, a first in class inhibitor of SUMOylation used in phase I/II clinical trials, has strong anti-leukemic activity, in particular when combined with Azacitidine, a DNA hypomethylating agent largely used in Acute Myeloid Leukemias. This synergy relies on the ability of SUMOylation to control Aza-induced transcriptional reprogramming. In a second part of my talk, I will present evidence for the implication of SUMOylation in the control of Natural Killer cells anti-leukemic activity through the regulation of the type-I interferon pathway.

